Quest Diagnostics Incorporated Stock News

Quest Diagnostics (DGX) collaborates with Envision Sciences to bring a novel prosate cancer biomarker test.

The Proov Confirm home collection kit can be purchased now on Quest Diagnostics' questhealth.com for $29.

Quest Diagnostics (DGX) is dedicated to create cutting-edge laboratory tests to help assess patient risk for dementia and other degenerative diseases.

Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.

SECAUCUS, N.J. , June 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter

Quest Diagnostics' (DGX) latest test indicates how different genes and their variants affect how a person reacts to drugs.

Quest Diagnostics (DGX) succeeds on contract wins in its reference and professional lab services offerings.

SECAUCUS, N.J. , June 2, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at th

Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and its strategies to accelerate growth.

The Meta Quest 3 is the successor to the Quest 2 headset that was released in the fall of 2020 at a starting price of $299.

Quest Diagnostics Incorporated has seen modest growth in recent years, although serial buybacks have increased growth on a per-share basis to attractive percentages. The company has been resilient and

Quest Diagnostics' revenue and earnings fell in Q1. The company's low payout ratio should support future dividend growth.

Patients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.

Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.

Quest Diagnostics' (DGX) first-quarter 2023 results are likely to reflect an impressive performance in its non-COVID-19 base business amid inflationary pressure and labor challenges.